Patient Monitoring

Part of Vaccines

Observing vaccinated individuals for expected reactions and identifying true adverse events requiring intervention.

Why This Matters

Vaccination does not end when the needle is withdrawn. Every vaccinated person requires monitoring — immediate observation for acute allergic reactions, followed by days to weeks of attention for delayed responses and signs of immune activation. This monitoring serves two purposes: protecting individual recipients from avoidable harm and generating the safety surveillance data that maintains confidence in the vaccination program.

In a well-run vaccination program, patient monitoring is systematic. In a resource-limited setting, it requires training recipients and their families to recognize important warning signs, combined with accessible pathways to report and receive assessment for concerning reactions.

The line between expected reaction and adverse event is defined by clinical observation. Without monitoring, that line cannot be drawn.

Immediate Observation (0-30 Minutes)

Every vaccinated person should remain at the vaccination site for 15-30 minutes after injection. This window captures anaphylactic reactions, which occur in the majority of cases within 15 minutes of injection.

What to watch for during immediate observation:

Skin:

• Generalized hives (urticaria) — multiple raised, itchy wheals spreading beyond injection site
• Widespread flushing
• Angioedema — swelling of lips, face, tongue, throat

Respiratory:

• Difficulty breathing, audible wheezing or stridor
• Voice change (suggests laryngeal edema)
• Rapid respiratory rate

Cardiovascular:

• Rapid, weak pulse
• Pallor, sweating, loss of color
• Dizziness or fainting
• Loss of consciousness

Gastrointestinal:

• Nausea, vomiting, abdominal cramping

Assessment protocol: Walk among waiting recipients at 5-10 minute intervals. Ask how they feel; observe visible signs. A worried practitioner’s instinct is a valid reason to examine more closely.

Grading acute reactions:

Grade	Symptoms	Action
1 (Mild)	Local urticaria only, or very mild systemic symptoms	Monitor closely; no epinephrine needed
2 (Moderate)	Generalized urticaria, mild angioedema, mild bronchospasm	Antihistamine; monitor for progression
3 (Severe)	Severe bronchospasm, severe angioedema, hypotension	Epinephrine immediately
4 (Anaphylaxis)	Shock, loss of consciousness, extreme respiratory compromise	Epinephrine, airway, emergency care

Emergency treatment for anaphylaxis:

1. Epinephrine (adrenaline) 0.5 mg IM in lateral thigh — this is the treatment. If no epinephrine is available, all other measures are supportive.
2. Lay person flat with legs elevated (unless respiratory distress — keep upright for breathing difficulty).
3. Maintain airway.
4. Monitor pulse and breathing continuously.
5. Repeat epinephrine after 5-15 minutes if no improvement.
6. Get to advanced care as quickly as possible.

If epinephrine is unavailable:

• Oral antihistamines (diphenhydramine if available, herbal anti-inflammatory preparations as alternatives)
• Positioning to maintain airway
• Supportive care
• These are inadequate substitutes for epinephrine in true anaphylaxis; acknowledge the limitation

Short-Term Monitoring (1-72 Hours)

Instruct every recipient and their family before they leave the vaccination site. Communication should be clear, brief, and in the recipient’s language.

Tell each recipient:

1. “Your arm will be sore, possibly red and swollen, for 2-3 days. This is normal.”
2. “You may feel tired and have mild fever (not burning hot) for 1-2 days. This is normal.”
3. “Come back immediately if: breathing difficulty, throat tightness, widespread rash, high fever that burns (over 39°C), swelling of the mouth or face.”
4. “Come back in 3 days if the injection site is getting more red, more painful, or swollen — not less.”

What to document at each follow-up contact or visit:

• Date and type of vaccine
• Date of reaction
• Symptoms: type, location, severity, duration
• Treatment given
• Outcome

Concerning short-term signs requiring evaluation:

Injection site:

• Increasing redness beyond 10 cm diameter
• Red streaking extending up the arm (suggests spreading cellulitis or lymphangitis)
• Severe pain preventing arm use
• Fluctuant swelling suggesting abscess formation
• Fever with local infection signs

Systemic:

• Fever > 39°C lasting more than 72 hours
• Fever > 40°C at any point
• Seizures (particularly in children)
• Severe headache persisting more than 48 hours
• Altered consciousness or unusual behavior
• Persistent vomiting
• Rash beyond the injection site

Monitoring Specific Vaccine Types

Vaccinia (Smallpox Vaccine)

Requires the most detailed monitoring of any common vaccine because the virus actively replicates.

Expected progression (document each stage):

• Day 3-4: small red papule (bump) at scarification site
• Day 5-6: vesicle (fluid-filled blister), 5-8 mm
• Day 7-9: pustule, surrounded by area of redness up to 20-30 mm; fever possible; axillary node tenderness
• Day 10-14: crust begins forming; systemic symptoms resolving
• Day 14-21: crust separates; scar remains

Failed take: No lesion or only a brief transient redness (pseudo-take) indicates no successful viral replication. Either:

• Pre-existing immunity (previous vaccination or prior smallpox)
• Inadequate inoculation technique
• Vaccine failure (inactivated or degraded material) Repeat vaccination with fresh material. If second attempt also fails, the person is likely already immune.

Adverse events requiring attention:

• Generalized vaccinia: scattered vaccinia lesions distant from inoculation site — represents viremia. Usually self-limiting in healthy individuals; requires monitoring.
• Progressive vaccinia: lesion continues to enlarge without healing; satellite lesions spread beyond original site. This is a medical emergency in immunocompromised individuals. Discontinue vaccinia; supportive care; antiviral if available.
• Eczema vaccinatum: if recipient has active eczema or skin conditions, vaccinia may spread across affected skin extensively. Screen for skin conditions before vaccinating; do not vaccinate active eczema.

BCG (Tuberculosis)

Expected reaction:

• Week 2-4: small papule at injection site
• Week 4-6: pustule or small ulcer (0.5-1 cm diameter); local lymph node enlargement possible
• Month 2-3: heals with characteristic flat scar

Monitoring: The ulcer stage alarms recipients who are not prepared for it. Instruct in advance. The ulcer should gradually heal. Concerns:

• Lymph node suppuration (abscess in regional lymph node, usually axillary) — requires attention if size > 3 cm or if fluctuant
• Disseminated BCG disease (extremely rare, occurs in severely immunocompromised individuals) — BCG-itis affecting multiple organs

Live Attenuated Viral Vaccines (Measles, etc.)

Expected: Mild measles-like illness 7-12 days after vaccination: low fever, faint rash, mild cold symptoms for 2-3 days. This is vaccine virus replication — significantly milder than natural measles.

Monitoring:

• Ensure recipients and families know to expect this 7-12 days post-vaccination, not immediately
• High fever (>39°C), severe rash, or central nervous system symptoms 7-12 days post-vaccination warrant evaluation — extremely rare but real adverse events exist

Adverse Event Reporting System

Even in a rebuilding context, a systematic adverse event reporting system is essential.

Minimum viable reporting system:

1. Standardized case report form (paper) — completed for every Grade 2 or higher adverse event
2. Regular (weekly or monthly) compilation of cases across all vaccinators
3. Review of compiled data for patterns — same vaccine lot, same time period, same population
4. Mechanism to communicate findings to vaccine production and program management

Reporting triggers:

• Any death temporally associated with vaccination (within 30 days)
• Any serious adverse event (hospitalization, anaphylaxis, encephalitis, paralysis)
• Any cluster of mild events from the same vaccine lot
• Any adverse event pattern different from expected

Causality assessment: Not every event after vaccination is caused by vaccination. Classify each reported event:

• Consistent causal link: known adverse event type with appropriate timing and no more plausible alternative cause
• Indeterminate: insufficient information, or multiple possible causes
• Coincidental: evidence points to non-vaccine cause

This classification prevents both under-attribution (missing real adverse events) and over-attribution (attributing coincidental illnesses to vaccination, which undermines program trust).

Long-Term Follow-Up

For novel vaccine preparations or new community vaccination programs, establish a longer-term follow-up:

• Review disease incidence in vaccinated population at 1 month, 3 months, 6 months, and 1 year after campaign
• Compare disease rates in vaccinated vs. unvaccinated areas or age groups
• Document individuals who were vaccinated and subsequently developed the target disease — these breakthroughs are important data

This longitudinal observation is how historical programs established the duration of protection from different vaccines under field conditions — knowledge that cannot be obtained from laboratory studies alone.